MYOZ2 (myozenin 2) is a sarcomeric Z-disc protein that functions as an intracellular binding protein linking Z-line components including alpha-actinin, gamma-filamin, TCAP/telethonin, and LDB3/ZASP, while modulating calcineurin signaling localization 1. The protein plays important roles in sarcomere organization and myofibrillogenesis. MYOZ2 mutations cause familial hypertrophic cardiomyopathy (HCM) 2, with identified mutations including S48P and I246M that affect highly conserved amino acids and cosegregate with disease 2. Pathogenesis appears independent of calcineurin activity, instead involving Z-disc abnormalities and altered phospho-ERK1/2 and JNK signaling 1. Beyond cardiac disease, MYOZ2 has broader clinical relevance: elevated expression in gastric cancer tissues correlates with increased migration, invasion, and poor prognosis 3, and MYOZ2 emerges as a candidate biomarker for myocardial fibrosis 4. Deletions affecting MYOZ2 have been identified in cholestasis patients 5. MYOZ2 variants also associate with left ventricular noncompaction severity 6. These findings position MYOZ2 as a multifunctional sarcomeric protein with significant cardiac and non-cardiac disease associations.